Current treatment in rheumatoid arthritis: a review including nanotechnology and gene therapy

سال انتشار: 1396
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 325

فایل این مقاله در 7 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_RCM-4-2_004

تاریخ نمایه سازی: 18 تیر 1398

چکیده مقاله:

Rheumatoid arthritis (RA) is a common inflammatory disease affecting approximately 1% of the adult population worldwide. Before new treatments were available, unchecked RA caused notable inability and mortality .It is now accepted that primary diagnosis and treatment are essential and useful. Progress in therapy of RA has made it possible to deeply influence signs and symptoms as the period that joint destructed in inflammatory arthritis. Earlier and more efficient treatment becomes visible to significantly improve the prognosis of this disease. In this article, the old and new methods for treatment rheumatoid arthritis and their limitation and benefits were reviewed. These methods include nonsteroidal anti-inflammatory drug (NSAIDs), glucocorticoids(GC) that are a class of steroid hormones, disease-modifying anti-rheumatic drugs (DMARDs), biological agents that can be divided in two groups of monoclonal antibodies and teeny molecules, bisphosphonate therapy, nanotechnology, oral tolerance, photodynamic therapy, gene therapy, bone marrow transplantation, liposomes, superparamagnetic iron oxide nano particles (SPIONs).

نویسندگان

Najmeh Malekzadeh

Department of Genetics, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran.

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Hashemi M, Atabaki M, Daneshvar H, et al. Association of ...
  • Yuan F, Quan LD, Cui L, et al. Development of ...
  • Sun J, Zhang Y, Liu L, et al. Diagnostic accuracy ...
  • Subhashini V, Mahalakshmi AM, Suresh B. Current clinical strategies in ...
  • Ho LJ, Lai JH. Small-molecule inhibitors for autoimmune arthritis: Success, ...
  • Widler L, Jaeggi KA, Glatt M, et al. Highly potent ...
  • Bamonti F, Fulgenzi A, Novembrino C, et al. Metal chelation ...
  • Tobón GJ, Youinou P, Saraux A. The environment, geo-epidemiology, and ...
  • Navarro Sarabia F, Blanco FJ, Álvaro Gracia JM, et al. ...
  • Lo SF, Wan L, Lin HC, et al. Association of ...
  • Urban MK. COX-2 specific inhibitors offer improved advantages over traditional ...
  • Furst DE. Meloxicam: selective COX-2 inhibition in clinical practice. Semin ...
  • Vanniasinghe AS, Bender V, Manolios N. Manolios, The potential of ...
  • Nasonov EL. New approaches to pharmacotherapy for rheumatoid arthritis: perspective ...
  • Quan L. Macromolecular Nanomedicine of Glucocorticoids for the Treatment of ...
  • Combe, B. Early rheumatoid arthritis: strategies for prevention and management. ...
  • Deighton C, Criswell LA. Criswell, Recent advances in the genetics ...
  • Scully CJ, Anderson CJ, Cannon GW. Cannon, Long-term methotrexate therapy ...
  • Sen D, Paul JR, Ranganathan P. Ranganathan, Pharmacogenetics in rheumatoid ...
  • Senolt L, Vencovský J, Pavelka K, et al. Prospective new ...
  • Li S, Zhang R, Li P, et al. Development of ...
  • Lundquist LM, Cole SW, Sikes ML. Sikes, Efficacy and safety ...
  • Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the ...
  • Ding H, Yang L, Du W, et al. Bisphosphonates for ...
  • Keizman D, Ish-Shalom M, Maimon N, et al. Are bisphosphonates ...
  • Romas E. bone loss inflamatory arthritis:mechanism and therapeutic approches with ...
  • Russell RG, Rogers MJ, Frith JC, et al. The pharmacology ...
  • Fick EM, Anzeneder T, Katalinic A, et al. Bisphosphonates and ...
  • Muehleman C, Green J, Williams JM, et al. The effect ...
  • Forsblad D’Elia H, Larsen A, Waltbrand E, et al. Radiographic ...
  • Min SY, Park KS, Cho ML, et al. Antigen-induced, tolerogenic ...
  • Lubberts E, Koenders MI, van den Berg WB. The role ...
  • Cho ML, Kang JW, Moon YM, et al. STAT3 and ...
  • Ju JH, Cho ML, Jhun JY, et al. Oral administration ...
  • Min SY, Hwang SY, Park KS, et al. Induction of ...
  • Rai P, Mallidi S, Zheng X, et al. Development and ...
  • Misra R, Acharya S, Sahoo SK. Cancer nanotechnology: application of ...
  • Rubinstein I, Weinberg GL. Weinberg, Nanomedicines for chronic non-infectious arthritis: ...
  • Angell C, Xie S, Zhang L, et al. DNA Nanotechnology ...
  • Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: ...
  • Pham CT. Nanotherapeutic approaches for the treatment of rheumatoid arthritis. ...
  • Ozbakir B, Crielaard BJ, Metselaar JM, et al. Liposomal corticosteroids ...
  • Alten R, Döring G, Cutolo M, et al. Hypothalamus-pituitary-adrenal axis ...
  • Bartneck M, Peters FM, Warzecha KT, et al. Liposomal encapsulation ...
  • Gomez-Barrena E, Lindroos L, Ceponis A, et al. Cartilage oligomeric ...
  • Butoescu N, Seemayer CA, Foti M, et al. Dexamethasone-containing PLGA ...
  • Prosen L, Prijic S, Music B, et al. Magnetofection: a ...
  • Balmayor ER, van Griensven M. van Griensven, Gene therapy for ...
  • Baum BJ. Gene therapy. Oral dis. 2014;20:115-118. ...
  • Quirke AM, Lugli EB, Wegner N, et al. Heightened immune ...
  • Mi Z, Lu X, Mai JC, et al. Identification of ...
  • Evans CH, Robbins PD, Ghivizzani SC, et al. Gene transfer ...
  • نمایش کامل مراجع